Andrea S. Blevins Primeau, PhD, MBA

Patients with cancer and COVID-19 had high rates of hospitalization and/or respiratory illness, particularly among those taking immunotherapy or those older than 65 years.

In a whole-exome analysis, the most common mutations occurred in TP53, and mutations in other known cancer-associated genes were identified in women with HPV-negative vulvar cancer.

Administering MD-MTX prophylaxis against CNS relapse of DLBCL appeared best as early as possible or following R-CHOP completion.

Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.

Patients with early-stage breast cancer who undergo mastectomy with or without reconstruction are at risk of prolonged opioid use.

Patients with previously untreated CLL with comorbidities continued to experience greater benefits with venetoclax-obinutuzumab compared with chlorambucil-obinutuzumab.

First-line treatment of early-stage, unfavorable classic Hodgkin lymphoma with nivolumab plus doxorubicin, vinblastine, and dacarbazine resulted in high response rates and PFS in a phase 2 study.

The FDA approved FoundationOne CDx as a companion diagnostic for detecting MET with an exon 14-skipping alteration to determine eligibility for capmatinib for NSCLC.

The Society of Gynecologic Oncology published recommendations to guide clinicians through shared decision making with patients about anticancer treatment.

Abemaciclib plus trastuzumab and fulvestrant significantly prolonged PFS compared with abemaciclib-trastuzumab or chemotherapy among previously treated women with advanced HR+/HER2+ breast cancer.